PACLITAXEL (TAXOL) TREATMENT FOR REFRACTORY OVARIAN-CANCER - PHASE-IICLINICAL-TRIAL

OBJECTIVE: Our aim was to determine the efficacy and toxicity of pacli taxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer.STUDY DESIGN: Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m(2) over 24 hours every 21 days with optional granulocyte colony-stimulati ng factor support. RESULTS: Paclitaxel was generally well tolerated. I n four patients bower perforation or fistula developed. After three cy cles 34% oi patients had stable disease and 25% of patients demonstrat ed a response, either partial or complete. After six cycles 24% of pat ients continued to respond. To date, six patients have achieved a comp lete response. CONCLUSION: A 25% response rate in patients with refrac tory ovarian cancer was observed, which was durable to six cycles.